Preclinical immunoPET/CT imaging using Zr-89-labeled anti-PD-L1 monoclonal antibody for assessing radiation-induced PD-L1 upregulation in head and neck cancer and melanoma

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

(2016) A. S. Mansfield et al.   ANNALS OF ONCOLOGY

PD-L1 Detection in Tumors Using [64Cu]Atezolizumab with PET

(2016) Wojciech G. Lesniak et al.   BIOCONJUGATE CHEMISTRY

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy

(2016) Abul Azad et al.   EMBO Molecular Medicine

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

(2016) S.H. Lim et al.   EUROPEAN JOURNAL OF CANCER

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors

(2016) Samit Chatterjee et al.   Oncotarget

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers

(2016) Michael Hettich et al.   Theranostics

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer

(2016) Jin Sheng et al.   Scientific Reports

Immune-priming of the Tumor Microenvironment by Radiotherapy

(2015) Vafa Shahabi et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity

(2015) Claire Vanpouille-Box et al.   CANCER RESEARCH

Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies

(2015) S. Heskamp et al.   CANCER RESEARCH

Imaging, Biodistribution, and Dosimetry of Radionuclide-Labeled PD-L1 Antibody in an Immunocompetent Mouse Model of Breast Cancer

(2015) Anders Josefsson et al.   CANCER RESEARCH

STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells

(2015) N. C. Schmitt et al.   MOLECULAR CANCER THERAPEUTICS

Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging

(2015) Roy L. Maute et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

(2015) Roberto Bellucci et al.   OncoImmunology

Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade

(2014) S. J. Dovedi et al.   CANCER RESEARCH

PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment

(2014) J. Li et al.   CANCER RESEARCH

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

Radiation-Induced IFN-  Production within the Tumor Microenvironment Influences Antitumor Immunity

(2014) A. A. Lugade et al.   JOURNAL OF IMMUNOLOGY

Comparison of Conjugation Strategies of Cross-Bridged Macrocyclic Chelators with Cetuximab for Copper-64 Radiolabeling and PET Imaging of EGFR in Colorectal Tumor-Bearing Mice

(2014) Dexing Zeng et al.   MOLECULAR PHARMACEUTICS

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity

(2011) B. C. Burnette et al.   CANCER RESEARCH

Positive Progress in ImmunoPET—Not Just a Coincidence

(2010) Katelyn E. McCabe et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS